Newsroom

Person wearing purple gloves performing chemical synthesis

News

For decades, tuberculosis (TB) has been one of the deadliest infectious diseases worldwide. Resistant strains of Mycobacterium tuberculosis are particularly problematic, as many established drugs are becoming increasingly ineffective against them. However, a research team from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Saarland University has now discovered a new family of natural substances that exhibit excellent activity against the TB pathogen. They have also investigated these substances so comprehensively that targeted further development is possible for the first time. The researchers have now published their findings in the journal Angewandte Chemie International Edition.

21.01.2026

HIPS

News

Two collaborative projects involving the Helmholtz Centre for Infection Research (HZI) are being funded with 100,000 euros each from the joint program "zukunft.niedersachsen" of the state of Lower Saxony and the Volkswagen Foundation. Both projects result from the collaboration between HZI and the MRC–University of Glasgow Centre for Virus Research (CVR), established in 2024 as part of a cooperation between the Helmholtz Association and the British Medical Research Council (MRC). The funded MARITH project will grow organoids from throat tonsil tissue to study the development of immunological memory in humans, while the ViReST project analyzes the sites of viral replication in respiratory infections and their impact on virus transmission.

20.01.2026

HZI Campus

News

The global skin care company Beiersdorf and the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) have entered into a long-term, exclusive partnership. In this collaboration they aim to investigate the role of the skin microbiome in maintaining healthy skin. The goal is to identify natural products produced by microorganisms on the skin that have a positive effect on skin balance. The project is based on extensive data sets on microorganisms that inhabit human skin.

13.01.2026

HIPS

News

Prof. Rolf Müller, Scientific Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Head of the Research Unit “Novel Antibiotics” at the German Center for Infection Research (DZIF), has been appointed to the Scientific Advisory Board of the European Partnership on One Health Antimicrobial Resistance (EUP OHAMR). HIPS is a site of the Helmholtz Centre for Infection Research (HZI) in collaboration with Saarland University.

12.01.2026

HIPS

Cryo-electron microscope image of the nuclease Cas12a3 with illustrated scissors

News

The CRISPR “gene scissors” have become an important basis for genome-editing technologies in many fields, ranging from biology and medicine to agriculture and industry. A team from the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg has now demonstrated that these CRISPR-Cas systems are even more versatile than previously thought. In cooperation with the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Utah State University (USU) in Logan (USA), the scientists have discovered a novel CRISPR defense mechanism: Unlike known nucleases, Cas12a3 specifically destroys transfer ribonucleic acids (tRNA) that are vital for protein production to shut down infected cells. The team published its findings today in the journal Nature.

07.01.2026

HZI Campus

HIRI

News

The gene scissors CRISPR-Cas are an important tool for genome editing. However, their functionality is limited because they rely on specific sequences to operate. Their ancient ancestors, on the other hand, may have been much more versatile. Rediscovering their forgotten abilities and harnessing them for biotechnological applications is the goal of the “RGNcestry” research project led by Chase Beisel, affiliated department head at the Helmholtz Institute for RNA-based Infection Research (HIRI). The European Research Council (ERC) is funding the project with ten million euros over a period of six years.

23.12.2025

HIRI

HZI in the media

... gehört habt: Phagen. Spoiler: Was am Helmholtz-Zentrum für Infektionsforschung (HZI) passiert, rettet im Zweifel Leben – ...

05.02.2026

Redaktionsnetzwerk Deutschland

Mattioli an: Am Helmholtz-Institut für RNA-basierte Infektionsforschung (HIRI), einem Standort des Braunschweiger Helmholtz-Zentrums für ...

04.02.2026

Universitätsklinikum Würzburg

MWK) und der VolkswagenStiftung hat das Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig das Großprojekt HUMAN ...

03.02.2026

Regional Heute

Im Programm HUMAN am Helmholtz-Zentrum für Infektionsforschung in Braunschweig entschlüsselt die nächste Generation Forschender das ...

03.02.2026

VolkswagenStiftung

Quelle: Pressemitteilung

Helmholtz-Zentrum für Infektionsforschung GmbH

03.02.2026

LaborPraxis

der Medizinischen Hochschule Hannover und des Helmholtz-Zentrums für Infektionsforschung wollen seltene rheumatische Erkrankungen des

02.02.2026

Niedersächsisches Landesjustizportal

MWK) und der VolkswagenStiftung hat das Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig das Großprojekt HUMAN ...

02.02.2026

juraforum.de

... an anderen Forschungseinrichtungen gearbeitet, beispielsweise am Helmholtz-Institut für Pharmazeutische Forschung Saarland. Was sind die ...

02.02.2026

Deutschlandfunk

waren mehrere Forschungseinrichtungen beteiligt, darunter das Helmholtz-Zentrum für Infektionsforschung . Die Ergebnisse erschienen im

02.02.2026

Münchner Merkur

Medicine (CiiM), which is a joint institution of the Helmholtz Center for Infection Research (HZI) and Hannover Medical School (MHH). Using

29.01.2026

Medical Xpress

... stumpfen ab“, erklärt Marc Brönstrup vom Helmholtz-Zentrum für Infektionsforschung in Braunschweig. Neue Antibiotika sind dringend ...

27.01.2026

Tvinfo.de

entered an exclusive research partnership with the Helmholtz Centre for Infection Research’s HIPS institute to investigate how the skin

22.01.2026

Simply Wall St News

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.